You are here

Home

Clinical Trials: Brain Diseases

Each Clinical Trial will open in a new browser window or tab.

Return to Clinical Trials Page

Posted: Thursday, September 15, 2022 - 12:00
A Multi-center, Randomized, Double-blind, Phase 2 Study, Evaluating JCPyV-specific T Cell Therapy for the Treatment of PML
Condition:   Progressive Multifocal Leukoencephalopathy
Intervention:   Biological: CE-VST01-JC
Sponsor:   Cellevolve Bio Inc
Not yet recruiting
Posted: Wednesday, August 24, 2022 - 12:00
A Multicenter, Randomized Trial to Assess Safety, and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
Conditions:   Hypoxic-Ischemic Encephalopathy;   Neonatal Asphyxia;   Neonatal Encephalopathy
Interventions:   Drug: Normal Saline along with standard treatment;   Drug: Sovateltide along with standard treatment
Sponsor:   Pharmazz, Inc.
Not yet recruiting
Posted: Thursday, August 11, 2022 - 12:00
Exercise Reset for Concussion in a Military Environment
Condition:   Brain Concussion
Intervention:   Behavioral: Aerobic Exercise
Sponsors:   State University of New York at Buffalo;   United States Department of Defense;   Children's Hospital of Philadelphia;   University of Pennsylvania;   University of North Carolina, Chapel Hill;   Geneva Foundation;   Quadrant Biosciences Inc.;   Center for Neuroscience and Regenerative Medicine (CNRM);   Axon Medical Technologies LLC
Not yet recruiting
Posted: Tuesday, June 28, 2022 - 12:00
Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.
Condition:   Parkinson's Disease
Interventions:   Biological: hAESCs treatment;   Biological: placebo (saline)
Sponsors:   Shanghai East Hospital;   Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Not yet recruiting
Posted: Thursday, April 7, 2022 - 12:00
The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia
Condition:   Frontotemporal Dementia
Intervention:   Drug: ET-STEM
Sponsor:   Samsung Medical Center
Not yet recruiting
Posted: Thursday, March 31, 2022 - 12:00
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
Condition:   Moderate to Severe Alzheimer's Disease
Interventions:   Drug: GV1001 Placebo;   Drug: GV1001 0.56mg;   Drug: GV1001 1.12mg
Sponsor:   GemVax & Kael
Not yet recruiting
Posted: Wednesday, March 23, 2022 - 12:00
Stem Cell Infusion in the Treatment of Patients With Neurological Complications After Ischemic Stroke
Condition:   Ischemic Stroke
Interventions:   Biological: UC-MSC infusion via intravenous route;   Biological: UC-MSC infusion via intrathecal route;   Other: standard stroke treatment and rehabilitation therapy
Sponsor:   Vinmec Research Institute of Stem Cell and Gene Technology
Recruiting
Posted: Wednesday, January 12, 2022 - 12:00
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
Condition:   Mild to Moderate Alzheimer's Disease
Interventions:   Drug: GV1001 Placebo;   Drug: GV1001 0.56mg;   Drug: GV1001 1.12mg
Sponsor:   GemVax & Kael
Not yet recruiting
Posted: Wednesday, December 22, 2021 - 12:00
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
Condition:   Multiple System Atrophy
Interventions:   Biological: Autologous Mesenchymal Stem Cells;   Other: Placebo
Sponsor:   Mayo Clinic
Recruiting
Posted: Wednesday, December 15, 2021 - 12:00
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Tourette Syndrome
Condition:   Tourette Syndrome
Intervention:   Biological: AlloRx
Sponsor:   The Foundation for Orthopaedics and Regenerative Medicine
Recruiting

Pages